Clinical trials sponsored by Vall d'Hebron Institute of Oncology

Phase breakdown

Conditions studied

Recruiting trials led by Vall d'Hebron Institute of Oncology

• A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.
  NCT07593820 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Combination Therapy for BRAF-V600E Metastatic CRCm
  NCT06411600 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)
  NCT06630611 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
  NCT05916755 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials is Vall d'Hebron Institute of Oncology recruiting for?

Vall d'Hebron Institute of Oncology is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.